Purchase this article with an account.
J. Beynat, A. Ben Mehidi, J. P. Aubert, A. M. Bron, P. G. Massin, C. P. Creuzot-Garcher; Retidiab®: Assessment of a Continuing Medical Education Website for the Improvement of Diabetic Retinopathy Management. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2083.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Aim: The aim of this study was to evaluate the ability of a continuing medical education (CME) website to improve the knowledge of ophthalmologists for the management of diabetic retinopathy (DR).
A World Wide Web site called RETIDIAB® was created. At their first connexion, users had to answer a first test in order to evaluate their baseline level. Then they could have free access to the entire website, any time they wanted, with no obligation of duration. The website was composed of a course and different kind of trainings which were multiple choice questionnaires (MCQ) focused on the course, interpretation of diabetics’ fundus photographs, and case reports. After surfing on each pages of RETIDIAB®, they had to perform a second assessment. Finally they were asked to fill a questionnaire to evaluate this software.
Seventy-seven participants were recorded. Among these users, 52 made only the first evaluation, and 19 tested the web site completely. They were residents for 73.7% and physicians in practice for 26.3%. There were 11 men and 8 women. There age was 25 to 41 years (27.7 ±3 years). We found a statistically significant progression between the first and the second evaluation (34% of good answers versus 54%; p<0.001). The average time which separated the first and the second evaluation was 40 days ±20. In addition, the users globally expressed a high level of satisfaction with respect to the site.
This study demonstrated the interest and the effectiveness of RETIDIAB®, a new CME website which is exclusively devoted to DR management.
This PDF is available to Subscribers Only